Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.
November 16, 2017
Previously, there were few HPV tests well suited to developing countries, but a new product—Xpert HPV—changes this by offering an accurate, real-time, self-contained, and easy to use molecular testing mechanism that can be used at the point-of-care.
September 12, 2017
In a presentation to a roundtable gathering of international think tanks in New York City, Stephen Ezell argued we are entering an era of renewed biomedical innovation marked by a wide range of new-to-the-world treatments for cancers, rare and chronic diseases, and other disorders.
August 31, 2017
President Widodo promised a renewed focus on innovation and economic growth. But his government has undermined its own strategic goals by badly weakening intellectual property laws that are critical for innovative industries are to thrive.
July 10, 2017
Fact of the Week: When Doctors Start Using Electronic Drug Referencing Systems, They Begin Prescribing Newly Released Generics up to Two Months Earlier Than Before
When doctors have better access to medicinal information through electronic drug referencing systems, they prescribe newly released generics up to two months sooner, writes John Wu in Innovation Files.
June 26, 2017
Fact of the Week: In the Last 60 Years, $400 Million Worth of Federally Funded Cancer Research Trials Added 3.3 Million Years to the Lives of U.S. Patients
In the last 60 years, $400 million invested over 23 federally funded cancer research trials added 3.34 million years to the lives of U.S. patients, writes John Wu in Innovation Files.
June 14, 2017
Comments to U.S. Department of Agriculture’s Animal and Plant Health Inspection Service on Genetically Engineered Organisms
ITIF submitted comments to the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service on its proposed revisions to regulations governing crops improved through biotechnology.
June 14, 2017
ITIF submitted comments to the Food and Drug Administration on how they should regulate foods derived from gene-edited plants.
June 6, 2017
Speeding Cures for Patients: How Congress Can Update the Prescription Drug User Fee Act to Spur Biopharmaceutical Innovation
For more than two decades, the Prescription Drug User Fee Act (PDUFA) has underpinned America’s leadership in biopharmaceutical innovation. Join ITIF for a discussion with policy experts, industry leaders, and patient advocates to discuss why a timely reauthorization of PDUFA is critical to the future of medical innovation.
May 30, 2017
Fact of the Week: Pharmaceutical Innovation Accounted for 73 Percent of the Increase in Life Expectancy in 30 Developing and Developed Countries From 2000 to 2009
Pharmaceutical innovation accounted for 73 percent of the increase in life expectancy (approximately 1.73 years) in 30 developing and developed countries from 2000 to 2009, writes John Wu in Innovation Files.
March 21, 2017
Bipartisan collaboration on the Hill has proven scant in the opening weeks of the Trump era, but the opportunity to reauthorize the Prescription Drug User Fee Act provides a welcome occasion for bipartisan comity while extending legislation that has played a foundational role in underpinning U.S. life-sciences leadership and helping bring safe, innovative cures to patients faster, writes Stephen Ezell in Innovation Files.